PTX - Banter and General Comments, page-158

Surprised there been no comments around this collab considering it sounds to be a product with similar mode of action to Cellpryme

immuno-oncology company Imugene and NeoImmuneTech, a T-cell-focused biopharmaceutical company based in Maryland, USA, have come together to evaluate Imugene’s allogeneic CAR T azer-cel in combination with NeoImmuneTech’s proprietary immune T-cell amplifier NT-I7 for the treatment of cancer.Combined, the two treatments are expected to lead to an increase in the number and cancer-fighting properties of a patient’s own T-cells during their treatment with azer-cel.NeoImmuneTech’s NT-I7 is the only long-acting human interleukin-7 (IL-7) cytokine in clinical stage development and has been found to play a key role in T-cell development and survival, boosting cancer fighting T-cell numbers, their health and functionality to enhance immune function and potentially provide improved cancer fighting benefits to patients.